CANADIAN CANCER TRIALS GROUP

LOCALIZED PROSTATE

GU DISEASE ORIENTED GROUP MEETING AGENDA
CHELSEA HOTEL, TORONTO, ON
ROOM: WREN

SATURDAY APRIL 29TH, 2017, 7:00 AM – 8:00 AM

CO-CHAIRS: T. NIAZI
SENIOR INVESTIGATOR: FRANCISCO VERA-BADILLO
STUDY COORDINATOR: ALEXANDER MONTENEGRO & P. STOS

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:
- To understand and address, through clinical and translational research, the disease burden associated with localized prostate cancer in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to localized prostate cancer.
- To update, review, and discuss recent results of clinical studies conducted by the Canadian Cancer Trials Group and/or by national/international collaborators.
- To provide mentoring opportunities for investigators new to clinical trial research.
- To understand and apply new clinical trial methodologies in the field of clinical research related to localized prostate cancer.

7:00 am Welcome T. Niazi

CCTG Lead Open TRIALS

7:05 am PR.19: A randomized phase II trial evaluating treatment outcome, acute and long-term toxicity of High Dose Rate Brachytherapy (HDRB) and Low Dose Rate Brachytherapy (LDRB) as monotherapy in localized prostate cancer.

E. Vigneault/ G. Morton

New TRIAL CONCEPTS

7:20 am External beam Radiation therapy + brachy boost vs External beam Radiation therapy + HDR brachy boost + short course hormonal therapy T. Niazi

continued on next page …
**STUDY UPDATES**

**7:35 am  PCS VI:** Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Standard Pelvic Radiation Therapy followed by HDR Brachy Boost for High Risk Adenocarcinoma of the Prostate

**PCS VIII:** The predictive value of coexisting TMPRSS2-ERG gene fusion and PTEN deletion in prostate cancer patients with biochemical failure status post salvage or radical radiation therapy

**7:50 am  Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP) initiative**

**8:00 am  Meeting Adjourned**